Donate
Suivez-nous sur Linked In
Suivez-nous sur Youtube

Where oncology and autoimmunity converge to accelerate
immunotherapies. CAR‑T cells, Bispecific antibodies, Immune Checkpoint Inhibitors drive Innovations for Patients.
One ambitious objective: to cure autoimmune diseases.

Decoding autoimmunity–cancer crosstalk to enable
curative immunotherapies.

Our Research Targets

INNOVATE

Developing
next-generation
Tools for Experimental
and Clinical
Immunotherapies

Understand

Decoding common
and opposite immune
regulation mechanisms
in Cancer and
Autoimmune Diseases

Treat

Clinical Trials
to test CAR-T
and Bispecific
Antibody Strategies

Teach

Advancing
Education
and Training in
Immunotherapies

Now, CAR‑T cells and Bispecific Therapies offer unprecedented hope with patients achieving lasting remission beyond two years.
FHU CARE² is pioneering this new frontier toward curative immunotherapies.

Prof. Xavier Mariette

“Our goal with FHU CARE²
is clear: transform scientific
knowledge into curative,
patient-centered
immunotherapies through
strong scientific
and clinical synergy.”

See on

Dr. Samuel Bitoun

“FHU CARE² opens a new
chapter at the crossroads
of cancer and autoimmunity —
connecting expertise
to drive real clinical
breakthroughs.”

See on

Dr. Camille Bigenwald

“With FHU CARE²,
we harness the power
of CAR T and Bispecific
Therapies to turn scientific
innovation into lasting
remission.”

Led by Samuel Bitoun, Camille Bigenwald and Xavier Mariette, FHU CARE²
federates clinicians, researchers, teachers and industry partners
across rheumatology, internal medicine, haematology,
nephrology, gastroenterology, neurology and haemato‑oncology
(AP-HP, Université Paris-Saclay, Inserm, Gustave Roussy, CEA, INRAE)
to drive translational excellence in immunotherapies.

Our latest publications

Distinct molecular pathways supporting Sjögren's Disease clusters and disease progression

Sacha E Silva-Saffar, Yann Nguyen, Raphaèle Seror, Jacques-Eric Gottenberg, Anna Niarakis, Xavier Mariette, Gaetane Nocturne

Arthritis Rheumatology | PMID: 42272274 DOI: 10.1002/art.70251 . 2026 Jun 11. doi: 10.1002/art.70251. Online ahead of print.

Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France.

Camille Bigenwald, Damien Roos-Weil, Arnaud Pagès, Zofia Hélias-Rodzewicz, Christiane Copie-Bergman, Marzieh Nashvi, Pierre Khneisser, Marie Parrens, Alexandra Traverse-Glehen, Isabelle Ray-Coquard, Loïc Ysebaert, Tony Marchand, Jérôme Razanamahery, Frédéric Charlotte, Antoine Neel, Gandhi Damaj, Jérémie Dion, Eve-Marie Nazal-Traissac, Stéphanie Tardy, Géraldine Salmeron, Hélène Monjanel, Ahmed Idbaih, Sébastien Héritier, Julien Haroche, Jean Donadieu, Jean-François Emile

Blood Adv. | 2025 May 27;9(10):2530-2541. doi: 10.1182/bloodadvances.2024015208. PMID: 40009752 PMCID: PMC12148392 DOI: 10.1182/bloodadvances.2024015208

See all Publications